← Back to Search

Baseline and Digital Storytelling (DST) for Vaccine-Preventable Diseases

N/A
Waitlist Available
Led By Alexis Koskan, Ph.D
Research Sponsored by Arizona State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (t1), t2 (after 4-week intervention), and t3 (2-months post-intervention)
Awards & highlights

Study Summary

This trial proposes a culturally-grounded intervention to reduce vaccine hesitancy in Hispanic/Latino families & increase their children's COVID-19 vaccine uptake.

Who is the study for?
This trial is for Hispanic parents or guardians of children under 18 who haven't had their COVID-19 vaccinations up to date. Participants must self-identify as Hispanic, be willing to communicate via text, and provide a photo of their child's immunization record.Check my eligibility
What is being tested?
The study tests if digital storytelling can reduce vaccine hesitancy among Hispanic parents. It involves comparing the effects of receiving culturally-tailored stories about vaccines with just getting basic information.See study design
What are the potential side effects?
Since this trial focuses on behavioral interventions like information sharing and storytelling, there are no direct medical side effects. However, participants may experience changes in attitudes towards vaccines.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (t1), t2 (after 4-week intervention), and t3 (2-months post-intervention)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (t1), t2 (after 4-week intervention), and t3 (2-months post-intervention) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Child's COVID-19 vaccine uptake
Intentions to vaccinate child(ren) against COVID-19
Parental COVID-19 vaccine hesitancy
Secondary outcome measures
Parents' attitudes about vaccinating their child(ren) against COVID-19
Parents' perceived behavioral control to vaccinate their child(ren) against COVID-19
Parents' perceived norms about vaccinating their child(ren) against COVID-19

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Baseline and Digital Storytelling (DST)Experimental Treatment2 Interventions
Once participants complete the consent, they will be asked to complete a baseline assessment using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DST arm. The intervention group participants will watch the four selected digital stories about COVID-19 vaccine experiences among Hispanic parents of children. Each story was made with voice, images, and sound (3-5 minutes each). Intervention group participants will complete the Time 2 (T2) online survey immediately after the DST intervention. Two months later, the investigators will contact all participants and ask them to complete another follow-up (T3) assessment of participants' vaccine hesitancy and COVID-19 vaccination behaviors (since T1 and T2).
Group II: Baseline and ControlActive Control2 Interventions
Once participants complete the consent, they will be asked to complete a baseline assessment using the web-based data collection platform, Research Electronic Data Capture before the random assignment to control arm. Control group participants will receive a CDC COVID-19 Vaccine Information Sheet appropriate for their child's age before completing the T2 assessment. Two months later, the investigators will contact all participants and ask them to complete another follow-up (T3) assessment of participants' vaccine hesitancy and COVID-19 vaccination behaviors (since T1 and T2).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Digital Storytelling Intervention
2019
N/A
~560

Find a Location

Who is running the clinical trial?

Arizona State UniversityLead Sponsor
283 Previous Clinical Trials
109,434 Total Patients Enrolled
2 Trials studying Vaccine-Preventable Diseases
181 Patients Enrolled for Vaccine-Preventable Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
1,963 Previous Clinical Trials
2,674,570 Total Patients Enrolled
Alexis Koskan, Ph.DPrincipal InvestigatorArizona State University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open slots available for participation in this clinical experiment?

"According to clinicaltrials.gov data, this trial is still active and recruiting patients - the initial posting was on December 1st 2023, with subsequent updates occurring on December 7th of that same year."

Answered by AI

What is the scope of participation in this research endeavor?

"Affirmative. According to the clinicaltrials.gov website, this medical experiment is currently recruiting participants; it was uploaded on December 1st 2023 and modified on the 7th of that same month. The trial requires 90 subjects from a single site to take part in it."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents
2024. "Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06036134.
All > Narcolepsy
~53 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top